Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Nektar Therapeutics

Headquarters: San Francisco, CA, United States of America
Year Founded: 1990
Status: Public
Industry Sector: HealthTechnology
CEO: Howard W. Robin
Number Of Employees: N/A
Enterprise Value: $130,378,730
PE Ratio: -1.39
Exchange/Ticker 1: NASDAQ:NKTR
Exchange/Ticker 2: N/A
Latest Market Cap: $150,407,104

BioCentury | Dec 7, 2024
Data Byte

At $1B, PTC-Novartis deal ties record for cash up front

But partnership lands fourth on overall upfront payment
BioCentury | Apr 30, 2024
Deals

Deals Report: BMS-Repertoire to develop vaccines for autoimmunity

Plus: Regeneron, Mammoth to make CRISPR-based gene editing therapies, and updates from Vertex-TreeFrog, Ono-Deciphera and more
BioCentury | Jan 23, 2024
Management Tracks

Siga names Diem Nguyen CEO

Plus: Fish & Richardson names Sawert as principal and updates from ImmunoBrain and DiaMedica
BioCentury | Dec 7, 2023
Product Development

The first-in-human immuno-oncology problem

Companies face growing challenges in deciding whether to advance an immuno-oncology program based on early Phase I data
BioCentury | Nov 15, 2023
Deals

Alkermes oncology spinout Mural charts its future

Newly independent cancer biotech looks to twin 2025 readouts of IL-2 program that leads pipeline of engineered cytokine therapeutics
BioCentury | Aug 8, 2023
Deals

Aug. 7 Quick Takes: Eyeing cash, Ikena buys Pionyr 

Plus: Astellas’ Zimura approved for geographic atrophy, Bavarian’s chikungunya vaccine heading to regulators and updates from Gracell, IO, Sage, Nektar and DotBio
BioCentury | Aug 4, 2023
Management Tracks

Karuna names new CFO and HR head

Plus: Freeman joins Zentalis as chief strategy officer, and updates from Complement, 
BioCentury | Feb 24, 2023
Regulation

Feb. 23 Quick Takes: FDA approves Sanofi’s once-weekly hemophilia A therapy

Plus: CMS stays the course on Alzheimer's NCD and updates from Blueprint, Apellis, AZ, Nektar, Keymed, Prilenia and more  
BioCentury | Feb 3, 2023
Management Tracks

Vessey to leave BMS in July

Plus: Nichols joining enGene as CEO and updates from Invivyd, Exai and more
BioCentury | Oct 28, 2022
Product Development

Oct. 28 Quick Takes: Gilead returns to $100B market cap on strong earnings

Plus: vaccines stand out for Sanofi, and updates from Outlook, PTC, Y-mAbs, Ascletis, Agios and more
Items per page:
1 - 10 of 532